BioCryst Pharma (BCRX) Tops Q2 EPS by 1c; Sees Increase in Net Operating Cash

Article Stock Quotes (1) Comments (0)

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $5.44 million.

Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
• Gordmans Stores, Inc. (GMAN) Tops Q1 EPS Views; Issues Light Q2 Outlook
• Zumiez, Inc. (ZUMZ) Tops Q1 EPS by 1c; Guides In-Line

Create E-mail Alert Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?